Literature DB >> 26232179

The associations between PD-1, CTLA-4 gene polymorphisms and susceptibility to ankylosing spondylitis: a meta-analysis and systemic review.

Si Chen1, Yuan Li1, Chuiwen Deng1, Jing Li1, Xiaoting Wen1, Ziyan Wu1, Chaojun Hu1, Shulan Zhang1, Ping Li1, Xuan Zhang1, Fengchun Zhang1, Yongzhe Li2.   

Abstract

Previous surveys had evaluated the effects of the PD-1, CTLA-4 gene polymorphisms on susceptibility to ankylosing spondylitis (AS), but the results remained controversial. To briefly examine these consequences, a comprehensive meta-analysis was conducted to estimate the relationships between PD-1 rs11568821, rs2227982, rs2227981, CTLA-4 +49 A/G and -318 C/T polymorphisms and AS risk. The available articles dated to December 2014 were searched in the PUBMED, MEDLINE and EMBASE databases. The data of the genotypes and/or alleles for the PD-1 rs11568821, rs2227982, rs2227981, CTLA-4 +49 A/G and -318 C/T polymorphisms in the AS and control subjects were extracted, and statistical analysis was conducted by STATA 11.2 software. Summary odds ratios (ORs) with their 95 % confidence intervals (95 % CIs) were calculated to determine the strength of associations with fixed-effects or random-effects models. A total of eight published studies were finally involved in this meta-analysis. Meta-analysis of PD-1 rs2227982 polymorphism under the T allele versus C allele (OR 1.744, 95 % CI 1.477-2.059, P < 0.0001), TT+TC versus CC (OR 2.292, 95 % CI 1.654-3.175, P < 0.0001), TT versus CC (OR 1.883, 95 % CI 1.299-2.729, P = 0.001) revealed a significant association with AS. Our meta-analysis demonstrated that the rs2227982 polymorphism in the PD-1 gene might contribute to AS susceptibility. However, further studies with large sample sizes and among different ethnicity populations should be required to confirm this association.

Entities:  

Keywords:  Ankylosing spondylitis; CTLA-4; Meta-analysis; PD-1; Polymorphisms

Mesh:

Substances:

Year:  2015        PMID: 26232179     DOI: 10.1007/s00296-015-3327-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  44 in total

1.  Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis.

Authors:  M A Brown; S H Laval; S Brophy; A Calin
Journal:  Ann Rheum Dis       Date:  2000-11       Impact factor: 19.103

2.  CTLA-4 regulates cell cycle progression during a primary immune response.

Authors:  Rebecca J Greenwald; Mariette A Oosterwegel; Diane van der Woude; Anup Kubal; Didier A Mandelbrot; Vassiliki A Boussiotis; Arlene H Sharpe
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

Review 3.  Genetics of ankylosing spondylitis.

Authors:  M A Brown; B P Wordsworth; J D Reveille
Journal:  Clin Exp Rheumatol       Date:  2002 Nov-Dec       Impact factor: 4.473

Review 4.  Global prevalence of ankylosing spondylitis.

Authors:  Linda E Dean; Gareth T Jones; Alan G MacDonald; Christina Downham; Roger D Sturrock; Gary J Macfarlane
Journal:  Rheumatology (Oxford)       Date:  2013-12-09       Impact factor: 7.580

5.  Influence of sinomenine on protein profiles of peripheral blood mononuclear cells from ankylosing spondylitis patients: a pharmacoproteomics study.

Authors:  Zhi-xiang Huang; Jin-hui Tan; Tian-wang Li; Wei-ming Deng; Ke-wei Qiu; Ze-tao Liao; Zhao-qiu Zeng
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

6.  Association of polymorphisms in the programmed cell death 1 (PD-1) and PD-1 ligand genes with ankylosing spondylitis in a Chinese population.

Authors:  Qingrui Yang; Yi Liu; Dongxia Liu; Yuanchao Zhang; Kun Mu
Journal:  Clin Exp Rheumatol       Date:  2011-02-23       Impact factor: 4.473

7.  Effects of genetic polymorphisms of programmed cell death 1 and its ligands on the development of ankylosing spondylitis.

Authors:  Chun-Huang Huang; Ruey-Hong Wong; James Cheng-Chung Wei; Ming-Dow Tsay; Wei-Chiao Chen; Hung-Yin Chen; Wei-Ting Shih; Sz-Ping Chiou; Yi-Chung Tu; Hong-Shen Lee
Journal:  Rheumatology (Oxford)       Date:  2011-07-26       Impact factor: 7.580

8.  Association of CTLA4 gene polymorphism in Iranian patients with ankylosing spondylitis.

Authors:  Esfandiar Azizi; Ahmad Massoud; Ali Akbar Amirzargar; Mahdi Mahmoudi; Narjes Soleimanifar; Nima Rezaei; Ahmad Reza Jamshidi; Behrouz Nikbin; Mohammad Hossein Nicknam
Journal:  J Clin Immunol       Date:  2009-12-11       Impact factor: 8.317

9.  Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.

Authors:  John D Reveille; Anne-Marie Sims; Patrick Danoy; David M Evans; Paul Leo; Jennifer J Pointon; Rui Jin; Xiaodong Zhou; Linda A Bradbury; Louise H Appleton; John C Davis; Laura Diekman; Tracey Doan; Alison Dowling; Ran Duan; Emma L Duncan; Claire Farrar; Johanna Hadler; David Harvey; Tugce Karaderi; Rebecca Mogg; Emma Pomeroy; Karena Pryce; Jacqueline Taylor; Laurie Savage; Panos Deloukas; Vasudev Kumanduri; Leena Peltonen; Sue M Ring; Pamela Whittaker; Evgeny Glazov; Gethin P Thomas; Walter P Maksymowych; Robert D Inman; Michael M Ward; Millicent A Stone; Michael H Weisman; B Paul Wordsworth; Matthew A Brown
Journal:  Nat Genet       Date:  2010-01-10       Impact factor: 38.330

10.  Prevalence, clinical relevance and characterization of circulating cytotoxic CD4+CD28- T cells in ankylosing spondylitis.

Authors:  Christina Duftner; Christian Goldberger; Albrecht Falkenbach; Reinhard Würzner; Barbara Falkensammer; Karl P Pfeiffer; Elisabeth Maerker-Hermann; Michael Schirmer
Journal:  Arthritis Res Ther       Date:  2003-07-16       Impact factor: 5.156

View more
  8 in total

Review 1.  Autoimmunity and Cancer-Two Sides of the Same Coin.

Authors:  Justyna Sakowska; Łukasz Arcimowicz; Martyna Jankowiak; Ines Papak; Aleksandra Markiewicz; Katarzyna Dziubek; Małgorzata Kurkowiak; Sachin Kote; Karolina Kaźmierczak-Siedlecka; Karol Połom; Natalia Marek-Trzonkowska; Piotr Trzonkowski
Journal:  Front Immunol       Date:  2022-05-13       Impact factor: 8.786

2.  Association of rs10204525 genotype GG and rs2227982 CC combination in programmed cell death 1 with hepatitis B virus infection risk.

Authors:  Chunhong Huang; Tiantian Ge; Caixia Xia; Wei Zhu; Lichen Xu; Yunyun Wang; Fengtian Wu; Feifei Liu; Min Zheng; Zhi Chen
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

3.  Relationship of PD-1 (PDCD1) and PD-L1 (CD274) Single Nucleotide Polymorphisms with Polycystic Ovary Syndrome.

Authors:  Rui Han; Xiaoyun Gong; Yuejie Zhu; Xiaoran Liu; Yan Xia; Yuhong Huang; Meng Zhang; Yunian Zhang; Xiaolin La; Jianbing Ding
Journal:  Biomed Res Int       Date:  2021-01-04       Impact factor: 3.411

4.  Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism.

Authors:  Mizuki Kobayashi; Kazuyuki Numakura; Shingo Hatakeyama; Yumina Muto; Yuya Sekine; Hajime Sasagawa; Soki Kashima; Ryohei Yamamoto; Atsushi Koizumi; Taketoshi Nara; Mitsuru Saito; Shintaro Narita; Chikara Ohyama; Tomonori Habuchi
Journal:  Genes (Basel)       Date:  2022-07-05       Impact factor: 4.141

5.  Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients.

Authors:  Sander Bins; Edwin A Basak; Samira El Bouazzaoui; Stijn L W Koolen; E Oomen-de Hoop; Cor H van der Leest; Astrid A M van der Veldt; Stefan Sleijfer; Reno Debets; Ron H N van Schaik; Joachim G J V Aerts; Ron H J Mathijssen
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

6.  Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.

Authors:  Daan P Hurkmans; Edwin A Basak; Nina Schepers; Esther Oomen-De Hoop; Cor H Van der Leest; Samira El Bouazzaoui; Sander Bins; Stijn L W Koolen; Stefan Sleijfer; Astrid A M Van der Veldt; Reno Debets; Ron H N Van Schaik; Joachim G J V Aerts; Ron H J Mathijssen
Journal:  J Immunother Cancer       Date:  2020-05       Impact factor: 13.751

7.  Ankylosis progressive homolog upregulation inhibits cell viability and mineralization during fibroblast ossification by regulating the Wnt/β‑catenin signaling pathway.

Authors:  Xindong He; Yongqiang Dong
Journal:  Mol Med Rep       Date:  2020-10-11       Impact factor: 2.952

8.  Regulation of the immune tolerance system determines the susceptibility to HLA-mediated abacavir-induced skin toxicity.

Authors:  Takeshi Susukida; Saki Kuwahara; Binbin Song; Akira Kazaoka; Shigeki Aoki; Kousei Ito
Journal:  Commun Biol       Date:  2021-09-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.